Skip to main content

Table 1 Demographic and clinical characteristics of the patient population at baseline

From: Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors

  n = 40 patients
Age (years), mean (SD) 54.6 (14)
Females, n (%) 32 (80)
Disease duration (months), median (IQR) 38 (19–115)
DAS28, mean (SD) 4.87 (0.84)
SJC28, median (IQR) 4 (1.5–5.5)
TJC28, median (IQR) 8 (4–12.5)
VAS PtGA (mm), median (IQR) 65 (50–80)
HAQ-DI, median (IQR) 1.125 (0.75–1.5)
ESR (mm/1 h), median (IQR) 22 (18–36.5)
CRP (mg/dl), median (IQR) 0.9 (0.3–2.75)
12-joint GS index, median (IQR) 13 (8.5–18.5)
12-joint PD index, median (IQR) 2 (0–5.5)
IgM RF positive, n (%) 26 (65)
IgM RF titer (U/ml), median (IQR)a 85 (42.5–274)
IgG ACPA positive, n (%) 27 (67.5)
IgG ACPA titer (U/ml), median (IQR)a 66 (27.2–287.5)
Erosive disease, n (%)b 23/32 (71.9)
Current treatment with MTX, n (%) 36 (90)
Receiving corticosteroids, n (%) 31 (77.5)
Receiving NSAIDs, n (%) 9 (22.5)
Number of previous csDMARDs, median (range) 1 (0–3)
  1. aRF or ACPA titers in RF-positive or ACPA-positive patients respectively. ACPA titers > 340 U/ml were not diluted further
  2. bHands and feet X-ray data not available in eight patients
  3. SD standard deviation, IQR interquartile range, DAS28 Disease Activity Score in 28 joints, SJC28 swollen joint count in 28 joints, TJC28 tender joint count in 28 joints, VAS visual analogue scale, PtGA patient’s global assessment, HAQ-DI Health Assessment Questionnaire disability index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, GS gray scale, PD power Doppler, RF rheumatoid factor, ACPA anti-citrullinated peptide antibodies, MTX methotrexate, NSAID nonsteroidal anti-inflammatory drug, csDMARD conventional synthetic disease-modifying anti-rheumatic drug